Piper Sandler analyst Jessica Tassan lowered the firm’s price target on Oscar Health (OSCR) to $13 from $14 and keeps a Neutral rating on the shares. The firm notes the company reported mixed Q2 results last week, affirmed the revised 2025 guidance issued with the company’s July 22 preannouncement and articulated expectations for a return to profitability in 2026. Piper acknowledges significant questions around the revised 2025 guide and 2026 path to profitability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Moderately bullish activity in Oscar Health with shares up 1.3%
- Sell Rating for Oscar Health Amid Uncertainties in Guidance and Margin Improvement
- Oscar Health’s Earnings Call: Growth Amid Challenges
- Mixed options sentiment in Oscar Health with shares up 5.75%
- Cautious Outlook: Oscar Health’s Financial Challenges and Sell Recommendation Amid Industry Uncertainties